Zhejiang Orient Gene Biotech Management

Management Kriterienprüfungen 1/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Xiaoliang Fang

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	7.4yrs
Eigentum des Geschäftsführers	29.6%
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	7.4yrs

Jüngste Management Updates

Recent updates

Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) Weighed On By Its Debt Load?

Aug 20

Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) A Risky Investment?

Apr 30

Geschäftsführer

Xiaoliang Fang (67 yo)

7.4yrs

Amtszeit

CN¥1,152,900

Vergütung

Mr. Xiaoliang Fang is GM & Director of Zhejiang Orient Gene Biotech Co., Ltd. from April 18, 2017.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Xiaoliang Fang	GM & Director	7.4yrs	CN¥1.15m	29.62% CN¥ 1.1b
Xiaoping Han	Independent Director	7.4yrs	CN¥100.00k	keine Daten
Jianqiu Fang	Chairman	7.4yrs	CN¥1.25m	27.96% CN¥ 1.0b
Wei Lin	Independent Director	7.4yrs	CN¥100.00k	keine Daten
Haiying Feng	Chairman of the Board of Supervisors	7.4yrs	keine Daten	0.13% CN¥ 4.7m

7.4yrs

Durchschnittliche Betriebszugehörigkeit

59yo

Durchschnittliches Alter

Erfahrener Vorstand: 688298Die Vorstandsmitglieder gelten als erfahren (7.3 Jahre durchschnittliche Amtszeit).

Zhejiang Orient Gene Biotech Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

Zhejiang Orient Gene Biotech Co.,Ltd, Annual General Meeting, May 22, 2024

Recent updates

Second quarter 2024 earnings released: CN¥0.43 loss per share (vs CN¥0.41 profit in 2Q 2023)

Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) Weighed On By Its Debt Load?

Zhejiang Orient Gene Biotech Co.,Ltd to Report First Half, 2024 Results on Aug 30, 2024

New major risk - Revenue and earnings growth

Zhejiang Orient Gene Biotech Co.,Ltd, Annual General Meeting, May 22, 2024

Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) A Risky Investment?

Full year 2023 earnings released: CN¥1.97 loss per share (vs CN¥10.26 profit in FY 2022)

Now 21% undervalued after recent price drop

Zhejiang Orient Gene Biotech Co.,Ltd to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released: CN¥1.85 loss per share (vs CN¥10.26 profit in FY 2022)

Zhejiang Orient Gene Biotech Co.,Ltd (SHSE:688298) announces an Equity Buyback for CNY 100 million worth of its shares.

Now 21% undervalued after recent price drop

Third quarter 2023 earnings released: CN¥0.55 loss per share (vs CN¥1.54 profit in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.41 (vs CN¥3.35 in 2Q 2022)

Zhejiang Orient Gene Biotech Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Upcoming dividend of CN¥2.00 per share at 4.0% yield

First quarter 2023 earnings released: CN¥0.30 loss per share (vs CN¥12.30 profit in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥17.74 (vs CN¥29.29 in FY 2021)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥1.84 (vs CN¥3.12 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥4.02 (vs CN¥13.14 in 2Q 2021)

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Now 33% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Now 23% undervalued

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥4.37 (vs CN¥1.17 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥18.40 (vs CN¥3.96 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥9.89 (vs CN¥0.37 in 1Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥14.07 (vs CN¥0.91 in FY 2019)

New 90-day low: CN¥135

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

New 90-day high: CN¥203

Investor sentiment improved over the past week

New 90-day high: CN¥177

Market bids up stock over the past week

Softlab9 Technologies Inc. Purchases Rapid Antigen COVID Testing Kits from Zhejiang Orient Gene Biotech Co. Ltd

New 90-day low - CN¥123

New 90-day high - CN¥260

Geschäftsführer

Amtszeit

Vergütung

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter